

PLIVA - Lachema a.s.

[View the current PLIVA - Lachema a.s. Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/25497-PLIVA++Lachema+a.s..html)

(<http://www.bioportfolio.com/biocorporate/25497-PLIVA++Lachema+a.s..html>)

Contact Details:

Karásek 1

Tel: 420 541 127 111

Fax: 420 541 127 634

Email: lachema@lachema.cz

621 33 Brno,
Czech Republic

PLIVA - Lachema a.s. was established according to the incorporation plan for the state enterprise Lachema and a licence from the Ministry of Industry naming the company the legal successor of the state enterprise Lachema on 27 March 1991. However, the company's history goes back much further. The Lachema Brno state enterprise started to manufacture and finish and pack pure, laboratory and specialty chemicals more than a half century ago. During 1950s Lachema became a major manufacturer of analytical reagents and indicators, dyes for microscopy, sugars, amino acids and a range of other chemicals and bio-chemicals.

Recent Publications by PLIVA - Lachema a.s.:



- [Comparative anti-tumor efficacy of two orally administered platinum\(IV\) drugs in nude mice bearing human tumor xenografts.](#)
*The oral anti-tumor activity of a novel platinum(IV) complex, coded as...*28th June, 2006
Research and Development, PLIVA-Lachema a.s., Brno, Czech Republic.- *Anticancer Drugs*. 2006 Feb;17(2):201-6.
- [Pharmacokinetics and tissue distribution of platinum in rats following single and multiple oral doses of LA-12 \[\(OC-6-43\)-bis\(acetato\)\(1-adamantylamine\)amminedichloroplatinum\(IV\)\].](#)
*The pharmacokinetics of total and free plasma platinum (Pt) and Pt tissue...*27th April, 2005
PLIVA-Lachema a.s., Brno, Czech Republic.- *Int J Pharm*. 2005 Jan 6;288(1):123-9. Epub 2004 Nov 18. ([DOI Direct Link](#))
- [Platinum\(IV\) complex with adamantylamine as nonleaving amine group: synthesis, characterization, and in vitro antitumor activity against a panel of cisplatin-resistant cancer cell lines.](#)
*Procedure of the synthesis is described for new platinum(IV) drug LA-12...*23rd March, 2004
PLIVA-Lachema a.s., Karasek 1, 62133 Brno, Czech Republic.- *J Med Chem*. 2004 Jan 29;47(3):761-3. ([DOI Direct Link](#))

Press Releases on PLIVA - Lachema a.s.:

| | | | |
|---|----------------------|----------------------------|---|
| Reportlinker Adds Anticoagulants - A Global Market Review | 18th November, 2009 | Reportlinker | NEW YORK, Nov. 18 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Anticoagulants - A Global Market Review |
| Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim and Manufacturing Facility From PLIVA | 30th September, 2009 | Hospira, Inc. | LAKE FOREST, Illinois, September 30 /PRNewswire/ -- -- Expands Biologics Manufacturing/Commercial Capabilities -- Hospira, Inc. (NYSE: HSP), a global specialty pharmaceutical and medication |
| Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim | 30th September, 2009 | Hospira, Inc. | LAKE FOREST, Ill., Sept. 30 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), a global specialty pharmaceutical and medication delivery company, today announced the acquisition of worldwide rights |
| Warner Chilcott and Barr Announce Settlement of Femcon(R) Fe Patent Challenge | 22nd December, 2008 | Warner Chilcott Limited | ST. DAVID'S, Bermuda, Dec. 22 /PRNewswire-FirstCall/ -- Warner Chilcott Limited (Nasdaq: WCRX) today announced that its subsidiary Warner Chilcott Company, Inc. and Barr Laboratories, Inc., a |
| U.S. Federal Trade Commission Clears Teva's Acquisition of Barr | 19th December, 2008 | Barr Pharmaceuticals, Inc. | Closing scheduled for December 23, 2008 JERUSALEM, Israel and MONTVALE, N.J., Dec. 19 /PRNewswire-FirstCall/ -- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and Barr Pharmaceuticals, Inc. (NYSE |

BioNews Results for PLIVA - Lachema a.s.



- [Technology could save wasted money](#)
Pharmacy Europe: Nov 13 2009 11:36AM Matching: pliva
- [Right First Time: Pioneering New Methods Of Drug Manufacture](#)
Drug Discovery Online: Nov 12 2009 8:52AM Matching: pliva
- [Medicines sues generic drugmakers over Angiomax patent](#)
Cardiovascular Business: Oct 14 2009 8:09PM Matching: pliva

- [Hospira takes charge of biogeneric Neupogen](#)
Pharmafocus: Oct 14 2009 10:53AM Matching: pliva
- [Hospira takes charge of biogeneric Neupogen](#)
Pharmafocus: Oct 14 2009 9:36AM Matching: pliva
- [Medicines Co. sues Teva over Angiomax](#)
Haaretz: Oct 12 2009 1:54AM Matching: pliva
- [Medicines Company files patent infringement lawsuits](#)
Pharmacy Choice: Oct 12 2009 9:27PM Matching: pliva
- [The Medicines Company sues 3 cos on generic Angiomax](#)
PharmaBiz: Oct 12 2009 8:09AM Matching: pliva
- [The Medicines Company files lawsuit against Pliva Hrvatska for Angiomax\(R\)](#)
Individual.com: Oct 9 2009 7:12PM Matching: pliva
- [3 generic-drug makers are sued regarding Angiomax patent](#)
SmartBrief: Oct 9 2009 5:14PM Matching: pliva
- [The Medicines Company Files Patent Infringement Lawsuits](#)
Genetic Engineering News: Oct 9 2009 4:22PM Matching: pliva
- [Medicines Co. sues generic rivals over Angiomax](#)
Pharmacy Choice: Oct 9 2009 5:11AM Matching: pliva
- [Medicines Co. sues Teva and APP Pharma over patents supporting anti-clotting drug Angiomax](#)
San Francisco Examiner: Oct 8 2009 10:21PM Matching: pliva
- [The Medicines Company Files Patent Infringement Lawsuits](#)
Individual.com: Oct 8 2009 9:18PM Matching: pliva
- [Hospira acquires worldwide rights to biogeneric version of filgrastim & European facility from PLIVA](#)
PharmaBiz: Oct 3 2009 8:54AM Matching: pliva

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

